Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
16
INTS Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
-27.87%
Day range:
$0.31 - $0.34
52-week range:
$0.26 - $5.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
17.92x
Volume:
2.5M
Avg. volume:
3.2M
1-year change:
-93.39%
Market cap:
$6M
Revenue:
--
EPS (TTM):
-$1.05
Analysts' Opinion
-
Consensus RatingIntensity Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.50, Intensity Therapeutics has an estimated upside of 975.93% from its current price of $0.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.33.
Fair Value
-
According to the consensus of 3 analysts, Intensity Therapeutics has 975.93% upside to fair value with a price target of $3.50 per share.
INTS vs. S&P 500
-
Over the past 5 trading days, Intensity Therapeutics has overperformed the S&P 500 by 5.14% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Intensity Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intensity Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Intensity Therapeutics reported revenues of --.
Earnings Growth
-
Intensity Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intensity Therapeutics reported earnings per share of -$0.22.
Enterprise value:
5.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$6.4M | -$11.8M | -$15.2M | -$4.7M | -$3.4M | |
| EBITDA | -$6.4M | -$13.7M | -$15.1M | -$4.7M | -$3.4M | |
| Diluted EPS | -$1.58 | -$2.17 | -$1.05 | -$0.34 | -$0.22 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $3.3M | $745.1K | $11.2M | $1.7M | |
| Total Assets | -- | $3.7M | $951.5K | $12.4M | $3.1M | |
| Current Liabilities | -- | $4.4M | $6.9M | $2.5M | $2.6M | |
| Total Liabilities | -- | $14.5M | $16.9M | $2.7M | $2.7M | |
| Total Equity | -- | -$10.8M | -$16M | $9.7M | $334K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.9M | -$10.7M | -$12.8M | -$4.4M | -$2M | |
| Cash From Investing | -- | -$2.8M | $3.1M | $3.3M | -- | |
| Cash From Financing | $2.5M | $20.3M | $3.2M | $8K | $328K | |
| Free Cash Flow | -$4.9M | -$10.7M | -$12.8M | -$4.4M | -$2M | |
INTS
Sector
Market Cap
$6M
$34.4M
Price % of 52-Week High
6.49%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-93.39%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.32
200-day SMA
Sell
Level
$1.92
Bollinger Bands (100)
Sell
Level
0.3 - 1.96
Chaikin Money Flow
Buy
Level
4.6M
20-day SMA
Buy
Level
$0.31
Relative Strength Index (RSI14)
Sell
Level
42.98
ADX Line
Buy
Level
31.66
Williams %R
Neutral
Level
-41.2402
50-day SMA
Sell
Level
$0.39
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
30.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Stock Forecast FAQ
In the current month, INTS has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The INTS average analyst price target in the past 3 months is $3.50.
-
Where Will Intensity Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intensity Therapeutics share price will rise to $3.50 per share over the next 12 months.
-
What Do Analysts Say About Intensity Therapeutics?
Analysts are divided on their view about Intensity Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intensity Therapeutics is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Intensity Therapeutics's Price Target?
The price target for Intensity Therapeutics over the next 1-year time period is forecast to be $3.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is INTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intensity Therapeutics is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of INTS?
You can purchase shares of Intensity Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intensity Therapeutics shares.
-
What Is The Intensity Therapeutics Share Price Today?
Intensity Therapeutics was last trading at $0.33 per share. This represents the most recent stock quote for Intensity Therapeutics. Yesterday, Intensity Therapeutics closed at $0.33 per share.
-
How To Buy Intensity Therapeutics Stock Online?
In order to purchase Intensity Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
